Project Grant R03NS135197
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$161K
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
The federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), is supporting research at Case Western Reserve University (CWRU) to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The $107,948 award, effective January 9, 2025 through July 16, 2028, will employ ribosome profiling and RNA sequencing techniques to quantify the influence of hypoxia on translational...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $574,427 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Pittsburgh to investigate the role of amino acid metabolism in regulating glioblastoma growth and immune interactions. The research aims to elucidate the molecular and cellular mechanisms by which selective amino acid catabolism in glioblastoma cells can promote tumor progression...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support research to dissect the cellular composition and immune response within the glioblastoma (GBM) tumor microenvironment. The $687,279 award to Beth Israel Deaconess Medical Center, Inc. (Bidmc) will leverage archival patient samples and mouse models to uncover the...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $448,250 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Research Foundation for the State University of New York (RF SUNY) dba Upstate Medical Center. The 2-year project, running from August 1, 2024 to July 31, 2026, aims to target cell-scaffolding proteins to disrupt radioresistance in glioblastoma, an aggressive brain...
This Project Grant award of $449,203, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to investigate the mechanisms underlying the interaction between glioblastoma (GBM), the most aggressive brain tumor in adults, and the subventricular zone (SVZ) neurogenic niche. The research, conducted by Mayo Clinic Jacksonville, a nonprofit...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research on encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award, granted on May 6, 2025, with a completion date of March 31, 2030, aims to enhance the therapeutic efficacy of mesenchymal stem cell...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $460,940 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The University of Texas MD Anderson Cancer Center. This 2-year grant, effective June 1, 2025, will support research to investigate how glioma-associated germline risk alleles impact neurodevelopmental trajectories. Specifically, the research will leverage single-cell and bulk profiling...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The $609,749 award to the University of North Carolina at Chapel Hill aims to: Develop an injectable, biodegradable hydrogel scaffold that can deliver high concentrations of induced neural stem cells (iNSCs) for...
This $201,172 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by Duke University to develop a non-invasive biomarker for profiling glioblastoma, an aggressive and deadly brain tumor. The project aims to use cell-free DNA methylation patterns to overcome limitations of current diagnostic approaches that rely on invasive surgical procedures. By identifying a prognostic biomarker for longitudinal monitoring, the research...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $682,596 in funding to The University of Texas Southwestern Medical Center to investigate the metabolic mechanisms underlying glioma progression. The award aims to: Dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas. Determine the impact of aberrant metabolite secretion by glioma cells on excitability of the tumor...